Zorginstituut Nederland’s Lecanemab Healt...

By HEOR Staff Writer

February 18, 2026

Dutch Health Insurance Rejects Lecanemab Coverage Zorginstituut Nederland's advisory letter dated 13 February 2026 recommends against including lecanemab (Leqembi®) in the Dutch basi...
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
Strategic Vision and Infarmed 2026 Priorities for Regulatory Reform
Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package
Launch of TrumpRx Drug Pricing: Savings on Essential Medications
Ozempic Public Funding Approval in Portugal: Key Insights and Implications
Accelerating FAST-EU Clinical Trials
Trump Economic Revival: Key Policies and Impacts from Davos 2026
Navigating Economic Resilience Through Life Sciences Investment
Guiding Principles for Ethical AI Integration in Drug Development
EU Launches Joint Scientific Consultations to Enhance Health Technology Asses...
NHS Cost-Effectiveness Thresholds Boost Drug Approvals and Innovation
Driving Economic Transformation through Brain Health Investment in Africa